Group items tagged

India is in great need of developing a strong base for conducting medical and clinical research in the country. Medical research in India is still at large limited to some apex medical institutes and central laboratories.

US-based Spectrum Pharmaceuticals has announced that its new drug application (NDA) for Beleodaq has been accepted for filing by the FDA

Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.

Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology

US-based BioMarin Pharmaceutical has selected a new drug development candidate, BMN 250, for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB (MPS IIIB).

Advaxis, a biotechnology company developing the next generation of cancer immunotherapies, has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center at Georgia Regents University to conduct four Phase I/II clinical trials.

US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.

Celerion, a leader in early clinical research, is pleased to announce the expansion of clinical operations to South Korea.

US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).

EMA will launch a final round of targeted consultations with key stakeholders on its draft policy on proactive publication of and access to clinical-trial data at the beginning of May 2014.

PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF

Want to lose weight? Eat breakfast at seven.11 am and dinner at 6:14 pm

PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.

Combat the Easter chocolate binge with our selection of healthy eating and exercise apps. Easter has come and gone, leaving many of us with either a mountain of chocolate or a pile of empty boxes and a rather enlarged waistline.

PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.